The Time Lag Associated With the Reclassification of Germline BRCA Variants' Pathogenicity Is Critical for Cancer Patients

The period for reclassifying the variants' pathogenicity is too long for patients with advanced or recurrent cancers with variants of uncertain significance that can be objectively re-evaluated to be (likely) pathogenic according to accumulated evidence. At present, we have three breast cancer patients with the germline variant BRCA2 c.7847C>T, which was genetically evaluated to be likely pathogenic by the paper in Cancer Science.